Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1682 1683
This examiner grants 42% of resolved cases
Emma Ruth Hoppe is an examiner in Tech Center 1600 and Art Unit 1682. The record includes 38 resolved cases. An allowance rate of 42.1 percent is reported. This percentage serves as a benchmark for applicants evaluating their prospects. The median days to allowance is 1424. This period reflects the typical prosecution length for successful applications. Practitioners should use this figure to establish expected timelines.
The interview lift for Hoppe is 56.8 percent. This statistic indicates that conducting an interview significantly improves the probability of securing an allowance. The 56.8 percent interview lift is larger than the 42.1 percent allowance rate. For the 38 resolved cases, the median days to allowance of 1424 is a key metric for managing client expectations. In Art Unit 1682, the interview lift suggests that verbal communication is a highly effective strategy. This analysis provides a foundation for Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17908634 | PREDICTION OF RADIOTHERAPY RESPONSE FOR PROSTATE CANCER SUBJECT BASED ON IMMUNE DEFENSE RESPONSE GENES | Final Rejection | KONINKLIJKE PHILIPS N.V. |
| 18320148 | Systems and Methods for Assessing Mutational Burden of Neoplasms And Associated Treatments Thereof | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18251033 | METHOD FOR DETERMINING SENSITIVITY TO PARP INHIBITOR OR DNA DAMAGING AGENT USING NON-FUNCTIONAL TRANSCRIPTOME | Final Rejection | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18246529 | SIMULTANEOUS AMPLIFICATION OF DNA AND RNA FROM SINGLE CELLS | Final Rejection | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY |
| 17541117 | CLOSED NUCLEIC ACID STRUCTURES | Non-Final OA | GEN-PROBE INCORPORATED |
| 17666215 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | Final Rejection | ETH ZURICH |
| 18566982 | NEW NRG1 FUSIONS, FUSION JUNCTIONS AND METHODS FOR DETECTING THEM | Non-Final OA | MERUS N.V. |
| 17576975 | LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) ON A SOLID-PHASE MEDIUM | Final Rejection | Raytheon BBN Technologies, Corp. |
| 17576973 | LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) ON A SOLID-PHASE MEDIUM | Final Rejection | Raytheon BBN Technologies, Corp. |
| 17932244 | SYSTEMS AND METHODS OF DETECTING A RISK OF ALZHEIMER'S DISEASE USING A CIRCULATING-FREE MRNA PROFILING ASSAY | Non-Final OA | Superfluid Dx, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy